Dimerix

(ASX:DXB)

Investor Presentation

November 2021

Authorised for lodgment by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Dimerix

Dimerix | About Dimerix

About Dimerix

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases

Advancing **three near-term Phase 3** clinical studies



Demonstrated **clinical efficacy***; drug well understood, with **strong safety profile***

Patent protected products with **commercial manufacturing** established

Strong outlook with **significant value**** upside

Dimerix

* *ASX releases: 12Jul17, 18Oct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21*

** *See slides 11 and 14 for potential market potential*

Corporate overview

ASX	**Ticker Symbol**	**ASX:DXB**
	Share price	~A$0.27
	Total ordinary shares on issue	320,873,666
	Market Capitalisation	~A$87 million
	Average volume	1,177,054
	Cash Balance (30Sep21)	A$19 million*
	Top 20 Shareholders own	35%

*includes $10.3 million Placement and SPP funds received after quarter end

Top shareholders

Position	Holder Name	Holding	% IC
1	Mr Peter Meurs	44,179,309	13.8%
2	Merchant Group & Nominees	17,925,000	5.6%
3	Bavaria Bay Pty Ltd	7,316,992	2.3%
4	Yodambao Pty Ltd	6,362,603	2.0%
5	Solequest Pty Ltd & Nominees	3,187,302	1.0%
6	Pfleger Family A/C & Nominees	3,137,874	1.0%
7	Rubi Holdings Pty Ltd	2,500,000	0.8%
7	Mr Andrew & Mrs Melinda Coates	2,500,000	0.8%
8	Jampaso Pty Ltd & Nominees	2,377,355	0.7%
9	Mr Richard Stanley De Ravin	2,350,000	0.7%
10	Mr Taylor Nicholas Green	2,150,000	0.7%
TOTAL (TOP 10)		**49,807,126**	**29.3%**

Dimerix

Pathway towards commercialisation



✓ Phase 3 study in FSGS initiating, with other pipeline products also progressing

✓ Two independent Phase 3 clinical studies underway in patients with COVID-19 respiratory complications

✓ DMX-200 manufacturing process optimised to improve commercial scalability and global logistics

✓ Favourable clinical efficacy and strong safety profile across multiple Phase 2 renal clinical studies demonstrated

✓ Orphan Drug Designation/accelerated approval pathway granted by US FDA, EU EMA and UK MHRA for FSGS

Establishing

Validating

Growing

Dimerix

Development pipeline

5 product candidates in the pipeline, with 4 clinical opportunities



*subject to recruitment

DMX-200 – working on inflammatory signalling pathway



DMX-200
• Small molecule – new chemical entity
• Inhibits activity of a cellular receptor of inflammation: CCR2
• 240mg oral delivery daily - 120mg capsule administered twice daily
• Administered to patients already on angiotensin receptor blocker (ARB)
• Extensive regulatory engagement – orphan designation secured in US, EU and UK

Dimerix

Kidney Disease Development Overview

FSGS phase 3 study design

Recruitment of first patient anticipated Q4 2021

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB

Single, seamless Phase 3 study design

	Study Part 1 (n=~70)	**Study Part 2** (n-~180*)		**End**
DMX-200 + ARB	Recruit Part 1	Interim analysis	Accelerated Marketing Approval endpoint**	Final results
		Recruit Part 2		
Placebo + ARB	Recruit Part 1	Interim analysis		
		Recruit Part 2		

Dimerix

ARB: Angiotensin Receptor Blocker

* *Subject to review by biostatistician*

** *Accelerated Approval: Marketing approval for serious conditions that fill an unmet medical need based on a surrogate or an intermediate clinical endpoint*

Why FSGS: unmet need and market potential

FSGS: rare kidney disease characterized by inflammation and scarring of the kidney's filtration units, affecting children and adults^

Renal failure in <5 years from diagnosis – dialysis or transplant^

~20,000 FSGS patients in US with end-stage kidney disease - only ~1,000 receive kidney transplants each year^

Unfortunately, FSGS comes back to attack the new kidney 30-50% of the time^



Dimerix

*2018, IQVIA , Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments

Transparency Market Research, 2018, Focal Segmental Glomerulosclerosis (FSGS) Market, Global Industry Analysis, Size, Share,Growth, Trends, & Forecast 2017-2025

^ Nephcure Kidney International (2021); Focal Segmental Glomerulosclerosis https://nephcure.org/livingwithkidneydisease/understanding-glomerular-disease/understanding-fsgs [accessed 21Nov21]

COVID-19 Respiratory Complications

Potential benefits of DMX-200

Antiviral medications:
typically effective at preventing damage caused by a virus when administered
within 3-5 days of infection
(when many are asymptomatic)

DMX-200:
does not rely on early inhibition of viral replication –
DMX-200 aims to prevent damaging immune response regardless of vaccination or antiviral treatment

DMX-200:
may be beneficial for patients with a wide range of respiratory diseases in addition to COVID
(antivirals usually very specific for a virus and sometimes even the particular strain of the virus)

Dimerix

COVID-19 and pneumonia market potential



Dimerix

* *REMAP-CAP background: https://www.remapcap.org/background*
** *WHO COVID dashboard: https://covid19.who.int/*
*** *Dose and therefore cost varies with patient weight*

Two Phase 3 studies in COVID-19 patients

REMAP-CAP

REMAP-CAP: COVID-19 pneumonia in ICU

- >475 patients recruited to the study domain
- WHO endorsed study
- primary endpoint = 21 day mortality

Funded by European Union through H2020 "Rapid European COVID-19 Emergency Research response" (RECOVER) project

NHMRC Clinical Trials Centre

THE UNIVERSITY OF SYDNEY

CLARITY 2.0: COVID-19 respiratory complications

- Recruiting >600 patients in India and Australia
- Primary endpoint = 14 day WHO Clinical Health Score

Run through the NHMRC Clinical trials centre and the University of Sydney

Secondary endpoint: recovery and quality of life post hospitalisation (long-COVID assessment)

Initial study data anticipated Q1 2022

Dimerix

Additional longer term propositions

Additional asset value propositions

Longer term opportunities

Diabetic Kidney Disease



Addressable market

US$1.1 billion*

Key driver is the rise in diabetes global incidence



Chronic Obstructive Pulmonary Disease



Global COPD treatment market (2017)

US$14 billion**

Dimerix

* *2017 IQVIA ARB prescription and pricing data;*

** *https://www.marketwatch.com/press-release/chronic-obstructive-pulmonary-disease-copd-therapeutics-market-global-industry-analysis-trends-market-size-and-forecasts-up-to-2030-2021-11-10?tesla=y*

Corporate Outlook

Potential value driving events

2021

- ✓ DMX-200 demonstrated **encouraging clinical efficacy** and **strong safety profile** across multiple Phase 2 renal clinical studies
- ✓ Consistent advice received from **FDA, EMA and UK MHRA** on FSGS Phase 3 study design
- ✓ Orphan Drug Designation/**accelerated approval pathway** granted by US FDA, EU EMA and UK MHRA for FSGS
- ✓ Two independent Phase 3 clinical studies underway in patients with **COVID-19 respiratory complications**
- ✓ DMX-200 **manufacturing process optimised** to improve commercial scalability and global logistics
- ✓ DMX-700 in COPD progressed further towards **clinical development**
- ✓ Expansion of **IP portfolio**
- ✓ Strong **financial position**

2022

- ✓ FSGS **ethics approval** and clinical **site initiations**
- ❑ FSGS Phase 3 study **recruitment** and first patient **first dose**
- ❑ REMAP-CAP Phase 3 COVID-19 study recruitment and **top line data**
- ❑ CLARITY 2.0 Phase 3 COVID-19 study recruitment and **top line data**
- ❑ DMX-700 for Chronic Obstructive Pulmonary Disease progression towards **clinical study**
- ❑ Diabetic kidney disease **clinical study** design and next steps
- ❑ Further expansion of **IP portfolio**
- ❑ FSGS **Phase 3 study Part 1 analysis** and progression to Part 2

Dimerix